Non-exclusive drug discount agreement for Certolizumab pegol
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
Buyer may terminate Open-House if exclusive agreements are signed, typically 8-12 months after publication.
No guaranteed volumes; actual purchases depend on physician prescriptions and patient numbers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive framework agreement for supply of Certolizumab pegol
- Open-House model allows any qualifying pharmaceutical entrepreneur to join
Show full summary
Non-exclusive drug discount agreement for Certolizumab pegol (ATC L04AB05) via Open-House model. Only one lot. No estimated value. Participation open to qualifying pharmaceutical entrepreneurs. Agreement ends 31.10.2026. Buyer may terminate early if exclusive agreements are signed.
Risks
Buyer may terminate Open-House if exclusive agreements are signed, typically 8-12 months after publication.
No guaranteed volumes; actual purchases depend on physician prescriptions and patient numbers.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
Eligibility
- Submit self-declaration on exclusion grounds (§§123,124 GWB)
Administrative
- Submit self-declaration on Russia sanctions (EU Reg 833/2014)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Certolizumab pegol
Non-exclusive framework agreement for supply of Certolizumab pegol. Open-House model allows any qualifying pharmaceutical entrepreneur to join. No exclusivity, no minimum volume guarantee.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 24 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 551233-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
Buyer may terminate Open-House if exclusive agreements are signed, typically 8-12 months after publication.
No guaranteed volumes; actual purchases depend on physician prescriptions and patient numbers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications